AnaptysBio Non Operating Income Net Other vs Income Tax Expense Analysis
| ANAB Stock | USD 22.40 1.09 5.11% |
AnaptysBio financial indicator trend analysis is way more than just evaluating AnaptysBio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AnaptysBio is a good investment. Please check the relationship between AnaptysBio Non Operating Income Net Other and its Income Tax Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
Non Operating Income Net Other vs Income Tax Expense
Non Operating Income Net Other vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AnaptysBio Non Operating Income Net Other account and Income Tax Expense. At this time, the significance of the direction appears to have almost no relationship.
The correlation between AnaptysBio's Non Operating Income Net Other and Income Tax Expense is 0.14. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of AnaptysBio, assuming nothing else is changed. The correlation between historical values of AnaptysBio's Non Operating Income Net Other and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of AnaptysBio are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Non Operating Income Net Other i.e., AnaptysBio's Non Operating Income Net Other and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | 0.14 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Non Operating Income Net Other
Income Tax Expense
Most indicators from AnaptysBio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.57, whereas Tax Provision is forecasted to decline to (4.2 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.5M | 21.1M | 18.1M | 19.0M | Depreciation And Amortization | 2.1M | 2.3M | 2.4M | 2.0M |
AnaptysBio fundamental ratios Correlations
Click cells to compare fundamentals
AnaptysBio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AnaptysBio fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
| Short Long Term Debt Total | 2.2M | 342K | 21.0M | 19.5M | 17.8M | 10.8M | |
| Other Current Liab | 871K | 15.3M | 12.9M | 21.6M | 31.0M | 32.5M | |
| Total Current Liabilities | 29.5M | 19.8M | 16.1M | 26.1M | 37.4M | 19.3M | |
| Total Stockholder Equity | 405.0M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
| Property Plant And Equipment Net | 1.6M | 1.8M | 21.8M | 20.0M | 18.3M | 19.2M | |
| Net Debt | (168.8M) | (250.1M) | (474.8M) | (51.9M) | (18.2M) | (19.1M) | |
| Retained Earnings | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (614.1M) | (583.4M) | |
| Accounts Payable | 16.2M | 4.2M | 1.7M | 2.8M | 4.7M | 4.2M | |
| Cash | 171.0M | 250.5M | 495.7M | 71.3M | 36.0M | 34.2M | |
| Non Current Assets Total | 57.5M | 20.0M | 89.2M | 163.2M | 45.6M | 53.5M | |
| Non Currrent Assets Other | 208K | 1.5M | 662K | 256K | 230.4K | 218.9K | |
| Cash And Short Term Investments | 374.2M | 393.7M | 548.1M | 441.2M | 390.9M | 295.2M | |
| Common Stock Shares Outstanding | 27.1M | 27.3M | 27.4M | 28.2M | 26.9M | 21.0M | |
| Liabilities And Stockholders Equity | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
| Non Current Liabilities Total | 654K | 4.6M | 270.5M | 322.2M | 326.8M | 343.2M | |
| Other Current Assets | 3.5M | 2.9M | 4.9M | 4.5M | 9.1M | 9.5M | |
| Other Stockholder Equity | 213.5M | 660.7M | 678.6M | 717.8M | 703.0M | 738.1M | |
| Total Liab | 30.2M | 19.8M | 286.6M | 348.3M | 364.3M | 382.5M | |
| Property Plant And Equipment Gross | 1.6M | 1.8M | 21.8M | 20.0M | 24.5M | 25.7M | |
| Total Current Assets | 377.7M | 396.6M | 553.9M | 447.2M | 406.8M | 300.8M | |
| Accumulated Other Comprehensive Income | 338K | (4K) | (422K) | (5.2M) | (797K) | (836.9K) | |
| Short Term Debt | 2.2M | 342K | 1.5M | 1.6M | 1.8M | 2.3M | |
| Other Liab | 796K | 654K | 251.1M | 304.4M | 350.1M | 367.6M | |
| Net Tangible Assets | 405.0M | 396.7M | 627.0M | 584.3M | 672.0M | 705.6M | |
| Other Assets | 208K | 139K | 18.2M | 256K | 294.4K | 279.7K | |
| Property Plant Equipment | 3.0M | 1.8M | 2.3M | 2.1M | 2.4M | 1.6M | |
| Capital Surpluse | 648.7M | 660.7M | 678.6M | 717.8M | 825.5M | 517.6M | |
| Retained Earnings Total Equity | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (405.4M) | (385.2M) | |
| Short Term Investments | 203.2M | 143.2M | 52.4M | 369.9M | 354.9M | 252.1M | |
| Capital Lease Obligations | 871K | 342K | 21.0M | 19.5M | 17.8M | 9.4M | |
| Net Invested Capital | 406.4M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
| Long Term Investments | 54.3M | 17.5M | 67.1M | 142.9M | 27.0M | 25.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.